Cargando…
Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure
To date, the United States Food and Drug Administration (FDA) has approved four drugs to mitigate hematopoietic acute radiation syndrome and all four are repurposed radiomitigators. There are several additional drug candidates currently under evaluation that may also be helpful for use during a wide...
Autores principales: | Li, Yaoxiang, Girgis, Michael, Wise, Stephen Y., Fatanmi, Oluseyi O., Seed, Thomas M., Maniar, Manoj, Cheema, Amrita K., Singh, Vijay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169671/ https://www.ncbi.nlm.nih.gov/pubmed/34075191 http://dx.doi.org/10.1038/s41598-021-91067-9 |
Ejemplares similares
-
Analysis of
the Proteomic Profile in Serum of Irradiated
Nonhuman Primates Treated with Ex-Rad, a Radiation Medical Countermeasure
por: Carpenter, Alana D., et al.
Publicado: (2023) -
Comparative proteomic analysis of serum from nonhuman primates administered BIO 300: a promising radiation countermeasure
por: Girgis, Michael, et al.
Publicado: (2020) -
A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol
por: Cheema, Amrita K., et al.
Publicado: (2017) -
Microbiome study in irradiated mice treated with BIO 300, a promising radiation countermeasure
por: Cheema, Amrita K., et al.
Publicado: (2021) -
Metabolomic Studies of Tissue Injury in Nonhuman Primates Exposed to Gamma-Radiation
por: Cheema, Amrita K., et al.
Publicado: (2019)